Effect of the Novel Antiplatelet Agent Cilostazol on Plasma Lipoproteins in Patients With Intermittent Claudication
Authors:
- M. B. ElamMEM. B. Elam
- J. HeckmanJHJ. Heckman
- J. R. CrouseJCJ. R. Crouse
- D. B. HunninghakeDHD. B. Hunninghake
- J. A. HerdJHJ. A. Herd
- M. DavidsonMDM. Davidson
- I. L. GordonIGI. L. Gordon
- E. B. BorteyEBE. B. Bortey
- W. P. ForbesWFW. P. Forbes
- 1 December 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 18 (12) , 1942-1947
Abstract
—Cilostazol is an antiplatelet agent and vasodilator marketed in Japan for treatment of ischemic symptoms of peripheral vascular disease. It is currently being evaluated in the United States for treatment of symptomatic intermittent claudication (IC). Cilostazol has been shown to improve walking distance in patients with IC. In addition to its reported vasodilator and antiplatelet effects, cilostazol has been proposed to have beneficial effects on plasma lipoproteins. We examined the effect of cilostazol versus placebo on plasma lipoproteins in 189 patients with IC. After 12 weeks of therapy with 100 mg cilostazol BID, plasma triglycerides decreased 15% ( P P P 140 mg/dL) experienced the greatest changes in both HDL-C and triglycerides with cilostazol treatment. In that subset of patients, HDL-C was increased 12.2% and triglycerides were decreased 23%. With cilostazol, there was a trend (3%) toward decreased apoB as well as increased apoA1, resulting in a significant (9.8%, P P =0.0015) and a 9.03% increase in ankle-brachial index ( P <0.001). These results indicate that in addition to improving the symptoms of IC, cilostazol also favorably modifies plasma lipoproteins in patients with peripheral arterial disease. The mechanism of this effect is currently unknown.Keywords
This publication has 18 references indexed in Scilit:
- Involvement of the Rapid Increase in cAMP Content in the Vanadate-Stimulated Release of Lipoprotein Lipase Activity from Rat Fat Pads.Biological and Pharmaceutical Bulletin, 1996
- Regulation of VLDL secretion in primary culture of rat hepatocytes: involvement of cAMP and cAMP‐dependent protein kinasesEuropean Journal of Clinical Investigation, 1994
- CilostazolCardiovascular Drug Reviews, 1993
- Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)JAMA, 1993
- The Relationship between Ankle‐Arm Index and Mortality in Older Men and WomenJournal of the American Geriatrics Society, 1993
- Mortality over a Period of 10 Years in Patients with Peripheral Arterial DiseaseNew England Journal of Medicine, 1992
- SERUM HIGH-DENSITY LIPOPROTEINS IN PERIPHERAL VASCULAR DISEASEThe Lancet, 1978
- Intermittent claudication: prevalence and risk factors.BMJ, 1978
- SERUM LIPIDS AND LIPOPROTEINS IN PERIPHERAL VASCULAR DISEASEThe Lancet, 1971
- Sur un dosage rapide du cholesterol lié aux α-et aux β-lipoprotéines du sérumClinica Chimica Acta, 1960